{'fraction_non_alphanumeric': 0.05101058710298364, 'fraction_numerical': 0.030317613089509143, 'mean_word_length': 4.7430939226519335, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Two years clinical outcomes of patients treated with EucaLimus Sirolimus Eluting Stents

To evaluate the 2-years clinical outcomes of consecutive patients in a real-world population who received the eucalimus drug eluting stent. This was a single-centre, retrospective registry analysis that reviewed the clinical data from all patients who were implanted with EucaLimus Sirolimus-Eluting Stents (SES) between November 2016 and May 2018. Clinical follow-up was performed at 25.6 ± 5.7 months post-implantation. The primary endpoint was Target Lesion Failure (TLF) as a composite of cardiac death, target vessel Q-wave or non-Q-wave Myocardial Infarction, Coronary Artery Bypass Graft (CABG) and clinically driven Target Lesion Revascularization (TLR). Secondary endpoint was Major Adverse Cardiovascular Events (MACE) as a composite of all-cause mortality, any Myocardial Infarction, and any repeat revascularization (includes all target and non-target vessel). In addition, Stent thrombosis (ST) was analysed at respective follow-up period. A total of 171 patients (mean age; 70.0 ± 11.9 years) received a eucalimus stent. Among those 127 (80.9%) patients had hypertension and 37 (25.0%) patients had diabetes mellitus. A total of 229 lesions were treated with the eucalimus SES (1.47 stents per patient). 36.3% of patients treated with lesion length ≥ 20 mm, 58.5 % presented Type B2/C lesions. At 25.6 ± 5.7 months follow-up, Target Lesion Failure (TLF) was observed in 2 (0.9%) patients. No cardiac death or myocardial infarct attributed to the target vessel was reported in any patient. Target lesion revascularization (TLR) occurred in 2 patients solved by PCI. Mayor adverse event rate (MACE) was observed in 8 patients (3.9%). No cardiac death, no myocardial infarction at all, 3 cases of non-cardiac death, two cases of TLR solved by PCI, two cases of TVR and one case of non-TVR occurred. No Stent thrombosis (ST) was reported at respective follow-up period. In our study the EucaLimus stent showed a favourable 2-years clinical performance in a real-world population.